secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001641489-23-000062
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics sells Reneo shares for $4.4M to fund cadisegliatin Phase 3
---------------------------------------------------------------------------

- Sold all Reneo common shares held under 2017 license for ~$4.4M gross proceeds.
- Proceeds support preparations for launch of cadisegliatin Phase 3 in type 1 diabetes.
- Remains eligible for up to $94.5M in clinical, regulatory & commercial milestones.
- Eligible for tiered royalties (mid-single to low teens) on potential net sales of mavodelpar.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000062/0001641489-23-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000062/vtvt-20231030.htm
  HTML page:      https://secwatch.observer/filing/0001641489-23-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer